AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 33.55% compared to Amgen, Inc.'s net margin of 20.83%. Amgen, Inc.'s return on equity of 95.55% beat Johnson & Johnson's return on equity of 33.27%.

Amgen, Inc. has a consensus price target of $332.70, signalling downside risk potential of -2.68%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could grow by 1.49%. Given that Johnson & Johnson has higher upside potential than Amgen, Inc., analysts believe Johnson & Johnson is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.454, which suggesting that the stock is 54.551% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Amgen, Inc. has a quarterly dividend of $2.38 per share corresponding to a yield of 2.79%. Johnson & Johnson offers a yield of 2.26% to investors and pays a quarterly dividend of $1.30 per share. Amgen, Inc. pays 119.05% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Amgen, Inc. quarterly revenues are $9.6B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Amgen, Inc.'s net income of $3.2B is lower than Johnson & Johnson's net income of $5.1B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.43x while Johnson & Johnson's PE ratio is 20.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.16x versus 5.86x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 33.55% compared to Amgen, Inc.'s net margin of 31.72%. Amgen, Inc.'s return on equity of 95.55% beat Eli Lilly & Co.'s return on equity of 106.26%.

Amgen, Inc. has a consensus price target of $332.70, signalling downside risk potential of -2.68%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,146.30 which suggests that it could grow by 9.33%. Given that Eli Lilly & Co. has higher upside potential than Amgen, Inc., analysts believe Eli Lilly & Co. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.454, which suggesting that the stock is 54.551% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Amgen, Inc. has a quarterly dividend of $2.38 per share corresponding to a yield of 2.79%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Amgen, Inc. pays 119.05% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Amgen, Inc. quarterly revenues are $9.6B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Amgen, Inc.'s net income of $3.2B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.43x while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.16x versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 33.55% compared to Amgen, Inc.'s net margin of 33.68%. Amgen, Inc.'s return on equity of 95.55% beat Merck & Co., Inc.'s return on equity of 39.63%.

Amgen, Inc. has a consensus price target of $332.70, signalling downside risk potential of -2.68%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.58 which suggests that it could grow by 6.54%. Given that Merck & Co., Inc. has higher upside potential than Amgen, Inc., analysts believe Merck & Co., Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.454, which suggesting that the stock is 54.551% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Amgen, Inc. has a quarterly dividend of $2.38 per share corresponding to a yield of 2.79%. Merck & Co., Inc. offers a yield of 2.98% to investors and pays a quarterly dividend of $0.85 per share. Amgen, Inc. pays 119.05% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Amgen, Inc. quarterly revenues are $9.6B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Amgen, Inc.'s net income of $3.2B is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.43x while Merck & Co., Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.16x versus 4.35x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 33.55% compared to Amgen, Inc.'s net margin of 21.74%. Amgen, Inc.'s return on equity of 95.55% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Amgen, Inc. has a consensus price target of $332.70, signalling downside risk potential of -2.68%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $846.85 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.454, which suggesting that the stock is 54.551% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Amgen, Inc. has a quarterly dividend of $2.38 per share corresponding to a yield of 2.79%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Amgen, Inc. pays 119.05% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.

Amgen, Inc. quarterly revenues are $9.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Amgen, Inc.'s net income of $3.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.43x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.16x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.